Biogen
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
CEOChristopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees7,605
Employees7,605
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded1978
Founded1978
Employees7,605
Employees7,605
BIIB Key Statistics
Market cap25.87B
Market cap25.87B
Price-Earnings ratio16.13
Price-Earnings ratio16.13
Dividend yield—
Dividend yield—
Average volume2.88M
Average volume2.88M
High today—
High today—
Low today—
Low today—
Open price$176.30
Open price$176.30
Volume0.00
Volume0.00
52 Week high$185.17
52 Week high$185.17
52 Week low$110.04
52 Week low$110.04
Stock Snapshot
Biogen(BIIB) stock is priced at $176.40, giving the company a market capitalization of 25.87B. It carries a P/E multiple of 16.13.
On 2025-12-31, Biogen(BIIB) shares started trading at $176.30, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 2.88M.
Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $185.17 and a low of $110.04.
Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $185.17 and a low of $110.04.
Analyst ratings
49%
of 35 ratingsBuy
45.7%
Hold
48.6%
Sell
5.7%
People also own
Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.